AbCellera Biologics Inc.
NASDAQ Global SelectTotal Valuation
AbCellera Biologics Inc. carries a market capitalization of 1.87B, placing it among publicly traded companies globally. Its enterprise value stands at 682.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.87B |
| Enterprise Value | 682.98M |
Share Statistics
AbCellera Biologics Inc. currently has 303.95M shares outstanding.
| Shares Outstanding | 303.95M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 13.23, and the price-to-book ratio stands at 1.41.
| PE Ratio | N/A |
| PS Ratio | 13.23 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | -8.93 |
| P/OCF Ratio | -6.83 |
Enterprise Valuation
| EV / Sales | 8.62 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
AbCellera Biologics Inc. maintains a current ratio of 14.05, meaning it holds 14.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.05 |
| Quick Ratio | 13.12 |
| Debt / Equity | 14.94 |
| Debt / EBITDA | -0.84 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -17.94 |
| Return on Assets (ROA) | -10.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -30.19M |
| Effective Tax Rate | N/A |
Stock Price Statistics
AbCellera Biologics Inc.'s stock has gained approximately 165.36797% over the past 52 weeks. The 50-day moving average sits at 4.28, while the 200-day moving average is 4.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | 165.36797% |
| 50-Day Moving Average | 4.28 |
| 200-Day Moving Average | 4.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AbCellera Biologics Inc. generated 79.21M in revenue and converted that into -143.96M in net income, yielding earnings per share of -0.48. EBITDA reached -167.02M, while operating income came in at -197.89M.
| Revenue | 79.21M |
| Gross Profit | N/A |
| Operating Income | -197.89M |
| Pretax Income | -174.15M |
| Net Income | -143.96M |
| EBITDA | -167.02M |
| EBIT | -197.89M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
AbCellera Biologics Inc. holds 504.73M in cash and equivalents against 140.18M in total debt, resulting in a net debt position of -77.06M. Total book value stands at 743.89M, with working capital of 617.30M providing operational flexibility.
| Cash & Cash Equivalents | 504.73M |
| Total Debt | 140.18M |
| Net Debt | -77.06M |
| Equity (Book Value) | 743.89M |
| Book Value Per Share | 2.48 |
| Working Capital | 617.30M |
Cash Flow
AbCellera Biologics Inc. produced -153.26M in operating cash flow over the past twelve months. After subtracting -35.97M in capital expenditures, free cash flow totaled -189.23M - equivalent to -0.63 per share.
| Operating Cash Flow | -153.26M |
| Capital Expenditures | -35.97M |
| Free Cash Flow | -189.23M |
| FCF Per Share | -0.63 |
Margins
AbCellera Biologics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -249.84 and net profit margin of -181.75 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -249.84 |
| Pretax Margin | -219.86 |
| Profit Margin | -181.75 |
| EBITDA Margin | -210.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.46 |
| FCF Yield | -11.20 |
Scores
AbCellera Biologics Inc. posts an Altman Z-Score of 1.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.76 |